ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.
Abstract readReview
In one paragraph
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between amyloid-β deposition and cognitive function in cognitively normal adults: a multilevel meta-analysis.Alzheimer's research & therapy · 2026Pooled it
- Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches.The journal of prevention of Alzheimer's disease · 2025Pooled it
- Excitation-inhibition imbalance links amyloid pathophysiology to cognition in non-demented individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Machine Learning and Multimodal Biomarker Discovery in Alzheimer's Disease.Brain sciences · 2026Review
- Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology.Neurology · 2026Article
- The Machine Learning Classification of Retinal Ganglion Cell Dendritic Texture in a 3xTg-Alzheimer's Disease Mouse Model.Diagnostics (Basel, Switzerland) · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Higher baseline CSF cortisol is associated with adverse 24-month tau-related, neuroimaging, and cognitive outcomes across the Alzheimer's disease continuum.European geriatric medicine · 2026Article
- Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Article
- The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer's Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Discovery-Driven Plasma Proteomics Identifies a Multi-Protein Signature for Amyloid PET Positivity: A Machine Learning Analysis of the Bio-Hermes Cohort.International journal of molecular sciences · 2026Article
- Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Dementia diagnostic deserts: workforce and geographic inequities in the diagnostic pathway for cognitive impairment.Health affairs scholar · 2026Article
- A new amyloid PET evaluation method using separated gray-matter histogram based on three-component model.Annals of nuclear medicine · 2026Article
- The relationship between alcohol use disorder, measures of cognitive decline, and Alzheimer disease biomarkers in middle aged and older adults.Alcohol, clinical & experimental research · 2026Article
- Blood-based biomarkers for Alzheimer's disease diagnosis: a joint position paper from the Italian Societies of Neurology (SIN) and of Clinical Biochemistry and Clinical Molecular Biology - Laboratory Medicine(SIBioC) and from the Autonomous Association affiliated with SIN for dementia (SINdem).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Potential Neuroprotective Role of GLP-2 in Alzheimer's Disease: Clinical Observations, Mechanistic Insights, and Comparison with GLP-1.International journal of molecular sciences · 2026Article
- Associations of amyloid biomarkers with brain and cognitive changes from imaging, spinal fluid, and plasma.medRxiv : the preprint server for health sciences · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Antoine LeuzyClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Ariane BollackThe Grove Centre, White Lion Road Buckinghamshire, GE HealthCare, Amersham, UK.
Daniela PellegrinoPharmaceutical Diagnostics, GE HealthCare, Via Privata Galeno, Milan, Italy.
Charlotte E TeunissenNeurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC Vrije Universiteit, Amsterdam, The Netherlands.
Renaud La JoieDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Gil D RabinoviciDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
Nicolai FranzmeierThe Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
Keith JohnsonGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Leslie M ShawDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Alexander ArkhipenkoPharmaceutical Diagnostics, GE HealthCare, Marlborough, Massachusetts, USA.
Suzanne E SchindlerDepartment of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Lawrence S HonigDepartment of Neurology, Taub Institute for Research on Alzheimer's Disease and Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
Alexis Moscoso RialWallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Michael SchöllWallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
Henrik ZetterbergThe Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowThe Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Gill FarrarThe Grove Centre, White Lion Road Buckinghamshire, GE HealthCare, Amersham, UK.
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7MThe Long Life Family StudyU19AG063893 · NIA · WASHINGTON UNIVERSITY · PI PAOLA SEBASTIANI · 2019 to 2026
$125.4MEarly Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MVascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Hyun-Sik Yang · 2010 to 2026
$50.2MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9MResearch Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1MEpidemiological and Genetic Investigations of Blood-Based Biomarkers for Alzheimer's Disease in the Multiethnic, Washington Heights, Inwood, Columbia Aging Project (WHICAP)R01AG072474 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, MANLY, JENNIFER JAIE · 2021 to 2025
$13.3MEarly Onset Alzheimer's Disease ConsortiumR56AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2017 to 2017
$7.7MDS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's DiseaseR01AG081394 · NIA · WASHINGTON UNIVERSITY · PI Jason J Hassenstab · 2023 to 2026
$6.0MReimagining Precision Medicine Approaches to AD DiagnosisR35AG072362 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POSSIN, KATHERINE LAUREL, RABINOVICI, GIL DAN · 2021 to 2025
$4.8MTargeting Lewy Body Specific Pathology Using BiomarkersU01NS100600 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HONIG, LAWRENCE S, MARDER, KAREN S · 2016 to 2020
$4.5MAD Strategic Fund, and Alzheimer's Association ADSF-21-831376-CAD Strategic Fund, and Alzheimer's Association ADSF-21-831377-CAD Strategic Fund, and Alzheimer's Association ADSF-21-831381-CAlzheimer AssociationAlzheimer Drug Discovery FoundationAlzheimer NetherlandsAlzheimer's Association SG-23-1061717Alzheimer's Association ZEN24-1069572Alzheimer's Association 2021 Zenith Award ZEN-21-848495Alzheimer's Association 2022-2025 SG-23-1038904American College of RadiologyBluefield Project, Olav Thon Foundation, Erling-Persson Family Foundation FO2022-0270County Councils, the ALF-agreement ALFGBG-813971County Councils, the ALF-agreement ALFGBG-965326Cure Alzheimer's fund, Rönström Family FoundationDeutsche ForschungsgemeinschaftDeutsche Parkinson GesellschaftDutch National Dementia StrategyERA PerMed ERAPERMED2021-184European Research Council ADG-101096455European Union Joint Program for Neurodegenerative Disorders JPND2019-466-236European Union Joint ProgrammeEuropean Union's Horizon Europe 101112145European Union's Horizon Europe 101132933European Union's Horizon Europe R01 AG081394-01GE HealthcareGHR Foundation, Swedish Research Council 2022-00775Harvard Aging Brain Study ADRC P30-AG-072979Harvard Aging Brain Study R01AG072474Harvard Aging Brain Study R21AG070768Harvard Aging Brain Study U19 ADNI4Harvard Aging Brain Study U19AG024904Health Holland, the Dutch Research Council 10510032120003Hjärnfonden, Sweden ALZ2022-0006Hjärnfonden, Sweden FO2017-0243Innovative Medicines Initiatives 3TR 831434Joint Undertaking 101034344Knut and Alice Wallenberg foundation 2022-0231Knut and Alice Wallenberg Foundation KAW2014.0363Knut and Alice Wallenberg Foundation KAW 2023.0371Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation 2020-O000028Marie Curie International Training Network 860197Marie Skłodowska-Curie 860197Munich Cluster for Systems Neurology EXC 2145 SyNergyMunich Cluster for Systems Neurology ID 390857198National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre 101053962National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre 201809-2016862National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre 2019-02397National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre 2022-01018National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre ALFGBG-71320National Institute of Aging R01AG083740National MS SocietyNational Research Foundation of Korea RS-2023-00263612Neurodegenerative Disease Research 2017-00915Neurodegenerative Disease Research 2022-00732Neurodegenerative Disease Research AF-930351Neurodegenerative Disease Research AF-939721Neurodegenerative Disease Research AF-968270Neurodegenerative Disease Research JPND2021-00694Neurodegenerative Disease Research UKDRI-1003NIA NIH HHS P01 AG019724NIA NIH HHS P01-AG019724NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG062422NIA NIH HHS P30-AG062422NIA NIH HHS P30 AG066462NIA NIH HHS R01 AG046396NIA NIH HHS R01 AG059013NIA NIH HHS R01 AG066107NIA NIH HHS R01 AG070941NIA NIH HHS R01 AG072474NIA NIH HHS R01 AG081394NIA NIH HHS R01 AG083740NIA NIH HHS R21 AG070768NIA NIH HHS R35 AG072362NIA NIH HHS R44 AG071388NIA NIH HHS R56 AG057195NIA NIH HHS U01 AG057195NIA NIH HHS U01-AG057195NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG063893NIHNINDS NIH HHS U01 NS100600NINDS NIH HHS U01NS100600NINDS NIH HHS U19AG063893Parkinson foundation of Sweden 1412/22Rainwater Charitable FoundationRegionalt Forskningsstöd 2022-1259Research of the European CommissionSahlgrenska Academy at the University of GothenburgShanendoah FoundationStrategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation AF-980907Swedish Alzheimer Foundation AF-994900Swedish Brain Foundation FO2021-0293Swedish Federal Government under the ALF agreement 2022-Projekt0080Swedish Research Council 2017-02869Swedish Research Council 2021-02678Swedish Research Council 2021-06545Swedish Research Council 2023-06188Swedish state under the agreement between the Swedish government and the County Councils, ALF-agreement ALFGBG-715986Swedish state under the agreement between the Swedish government and the County Councils, ALF-agreement ALFGBG-965240The Selfridges Group FoundationVästra Götaland Region R&D VGFOUREG-995510
Abstract
Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies. Although these biomarkers are comparable alternatives in research settings to determine Aβ status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient. This article provides a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and their current and future applications and contexts of use. The primary aim is to assist clinicians in making better-informed decisions about the suitability of each biomarker in different clinical situations, thereby reducing the risk of misdiagnosis or incorrect interpretation of biomarker results. HIGHLIGHTS: Recent advances have positioned Aβ PET and CSF biomarkers as pivotal in AD diagnosis. It is crucial to understand the differences in the clinical use of these biomarkers. A team of experts reviewed the state of Aβ PET and CSF markers in clinical settings. Differential features in the clinical application of these biomarkers were reviewed. We discussed the role of Aβ PET and CSF in the context of novel plasma biomarkers.
Indexed as
Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersPositron-Emission TomographyBrainHumansAmyloid beta-PeptidesBiomarkersAlzheimerAβ‐PETbiomarkersCSFdiagnosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.